GI Oncology
Advertisement
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
The approval is based on positive results from the phase III RATIONALE-306 study.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
Patients with refractory UGI cancers who participated in phase I trials saw benefits in late-line settings.
A new retrospective study has examined the use of 68Ga-DOTATATE PET/CT in all stages of disease.
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Challenges in designing and conducting clinical trials for patients with metastatic pancreatic ductal cancer are discussed.
The efficacy and safety of MEK inhibitors are compared to chemotherapy and other targeted therapies.
The KRAS G12R mutation is analyzed against other alterations in pancreatic adenocarcinoma, and research findings are shared.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Drs. Finn and Yopp discuss the challenges of defining high-risk patient populations in adjuvant therapy trials for HCC.
Nivolumab plus ipilimumab provided a higher OS and ORR rate, supporting the combination as a potential standard of care.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.